Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/JAA.S279061 http://scihub22266oqcxt.onion/10.2147/JAA.S279061 33116658!7575826!33116658     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Asthma+Allergy 2020 ; 13 (ä): 505-508 Nephropedia Template TP {{tp|p=33116658|t=2020. Asthma and COVID-19: In Defense of Evidence-Based SABA |pdf=|usr=}}{{33116658}} gab.com Text Asthma and COVID-19: In Defense of Evidence-Based SABA JO: J Asthma Allergy http://www.kidney.de/pget.php?&tw=1&pmid=33116658 #FOAvip There have recently been major objections to the use of short-acting beta-agonist (SABA) in episodic acute asthma culminating in a call for replacing SABA with combination of inhaled corticosteroids and long-acting beta-agonists despite little evidence supporting this point of view. It is regrettable to note that this attack on SABA occurs in the midst of an unprecedented demand for, and shortage of, SABA inhalers during the current COVID-19 pandemic, and the worldwide efforts to increase SABA supplies. In this commentary, we defend the well-established role of SABA and argue that the call for the phase out of SABA is inappropriate, since it is not solidly evidence based. Twit Text FOAVip Asthma and COVID-19: In Defense of Evidence-Based SABA ????J Asthma Allergy http://www.kidney.de/pget.php?&tw=1&pmid=33116658 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33116658 #FOAvip English Wikipedia <ref>{{Cite pmid|33116658}}</ref> Asthma and COVID-19: In Defense of Evidence-Based SABA #MMPMID33116658 Amirav I; Newhouse MT J Asthma Allergy 2020[]; 13 (ä): 505-508 PMID33116658show ga There have recently been major objections to the use of short-acting beta-agonist (SABA) in episodic acute asthma culminating in a call for replacing SABA with combination of inhaled corticosteroids and long-acting beta-agonists despite little evidence supporting this point of view. It is regrettable to note that this attack on SABA occurs in the midst of an unprecedented demand for, and shortage of, SABA inhalers during the current COVID-19 pandemic, and the worldwide efforts to increase SABA supplies. In this commentary, we defend the well-established role of SABA and argue that the call for the phase out of SABA is inappropriate, since it is not solidly evidence based. äAsthma and COVID-19: In Defense of Evidence-Based SABA (epmc).pdf DeepDyve Pubget Overpricing